It is well established that maternal uterine constraint and substrate availability to the fetus via the placenta are major determinants in fetal growth (1) . It has previously been thought that GH has little role in regulating fetal growth despite high concentrations of GH in the fetus and infants, but recently it has been shown that infants with congenital GH deficiency had a mean birth length that was 1 SD below the normal mean, suggesting that GH could have an effect on linear growth (2) or have a metabolic role (3) . Disruption of the IGF genes has demonstrated the importance of IGF-I, IGF-II, and their receptors in fetal growth in animal studies (4) and in humans (5) .
IGF-I synthesis in fetal tissues begins as early as 9 -19 wk of gestation (6) , and the dominant influence on fetal IGF levels at least in the second half of pregnancy seems to be the nutrient status, particularly the availability of glucose to the fetus and the consequent changes in fetal insulin release (7) . In early postnatal life, nutrition, insulin, and IGF-I still regulate growth to a large extent.
In early infancy, circulating GH levels are high and serum IGF-I concentrations are low compared with later childhood and in adult life (3, 8 -10) . The hypersomatotropinemia in infancy may result from a lack of negative feedback from the relatively low concentrations of circulating IGF-I and low levels of GH receptors in tissues of infants, suggesting a degree of GH resistance (11) (12) (13) . Postnatally the effects of GH on linear growth do not become prominent until late infancy. According to the Infancy-Childhood-Puberty growth model, human growth can be broken down into an infancy phase of growth, which is dependent on nutrition; a childhood phase of growth, which is dependent on hormones and growth factors (especially GH); and the pubertal phase of growth, during which both hormones and sex steroids have a significant effect (14) . It has been suggested that the onset of the childhood phase of growth, which is characterized by an abrupt increase in length velocity occurring usually in the second 6 mo of life, marks the time when GH starts to have a significant effect on linear growth (14) .
Although IGF-I is now well established to play an important role in postnatal growth (15) (16) (17) , the timing of the onset of GH dependence of serum total IGF-I and IGFBP-3 concentrations has not been clearly delineated. The usefulness of obtaining serum IGF-I and IGFBP-3 concentrations in infancy for the investigation of infants with growth problems is limited because normal values for this age group have not been well established. Detailed studies of the changes in the serum GHBP, IGF-I, and IGFBP-3 in the first 2 y of life are limited (3, 10, 12, 13, 16 -25) . We report here a longitudinal study of the serum GHBP, IGF-I, and IGFBP-3 concentrations in a group of normal Chinese babies in the first 18 mo of life and their correlations with growth during this period with a special reference to the onset of the childhood phase of growth.
METHODS
Forty-eight full-term Chinese babies (25 boys and 23 girls) with a birth weight between 2.7 and 4.0 kg, born to mothers without preexisting illness or pregnancy complications, were recruited into the study. The babies were followed up every 2 mo in the first year and every 3 mo during the second year of life. At each follow-up visit, anthropometric measurements (supine length, weight and head circumference) were taken using standardized techniques by one investigator (S.Y.M.T.), together with a complete physical examination by a pediatrician. Blood samples were taken at birth and at 6, 10, 12, and 18 mo after birth, and the serum samples were stored at Ϫ70°C until analysis for GHBP, IGF-I, and IGFBP3. The study was approved by the Ethics Committee, Faculty of Medicine, The University of Hong Kong, and written informed consent was obtained from the parents.
GHBP was determined in duplicate by an MAb assay (Endocrine Sciences, Calabasas Hill, CA, U.S.A.) by incubating the serum samples with excess radiolabeled human GH and an MAb. The intra-and interassay CVs were reported to be 5.6% and 9.5%, respectively. Serum IGF-I and IGFBP-3 were measured by two-site immunoradiometric assays supplied by Diagnostic Systems Laboratories Inc. (Webster, TX, U.S.A.). For the IGF-I assay, the intra-and interassay CVs were 3.2% and 6% at the level of 7.8 nM and 2.1% and 3.6% at the level of 26 nM. For the IGFBP-3 assay, the intra-and interassay CVs were 2.6% and 6.3% at the level of 15.8 nM and 3.6% and 6.9% at the level of 87.5 nM.
The age of onset of the childhood phase of growth was determined by visual inspection of the measured attained length and the change in growth velocity displayed on a computer-generated Infancy-Childhood-Puberty-based growth chart as previously described (26) . Babies with the onset age occurring between 6 and 10 mo of age would be regarded as the early onset group whereas those with onset occurring after 10 mo of age were referred to as the late-onset group.
The results were expressed as the mean and SD. The mean serum IGF-I and IGFBP-3 levels between the early and lateonset groups of babies at different ages were compared using the Wilcoxon two-sample test. The correlation of the serum growth factors with various measures was explored using the bivariate correlation coefficient (Spearman) at different ages and age intervals. Multiple linear regression was used to analyze the effects of serum growth factors on body length with adjustment made for sex, age of onset of childhood phase, and energy intake.
RESULTS
The mean gestational age, birth weight, and birth length of the babies are shown in Table 1 . The change in length during the first 2 y of life in the babies did not deviate significantly from the National Center of Health Statistics growth reference, and this had been previously reported (27) . The mean age of onset of the childhood phase of growth was 9.9 mo in boys and 9.6 mo in girls, which was not significantly different from that derived from a Swedish longitudinal growth study cohort (26) . Only one boy and one girl had an onset of the childhood phase of growth after 12 mo of age.
The serum IGF-I levels were not normally distributed, and the antilogarithmic mean and its 95% confidence intervals of the serum IGF-I values from birth to 18 mo are shown in Figure 1 . The serum GHBP, IGF-I, and IGFBP-3 concentrations between birth and 18 mo in the 48 infants are shown in Table 2 738 lation was found between the change in growth factors and change in length and BMI at other periods of the study. The 34 infants with onset of childhood phase of growth between 6 and 10 mo had a higher mean serum IGF-I value at 10 mo (8.8 Ϯ 5.8 nM versus 4.9 Ϯ 3.1 nM, p Ͻ 0.05) and higher length velocity between 10 and 12 mo (16.3 Ϯ 4.7cm/y versus 8.8 Ϯ 4.3cm/y, p Ͻ 0.001) compared with the 14 infants with a later onset after 10 mo of age (Fig. 4) . There was no significant difference in the serum IGFBP-3 and GHBP levels between the two groups. No correlation was found in these measurements between birth and 6 mo and between 12 and 18 mo. A significant correlation between a change in serum IGF-I and a change in serum IGFBP-3 levels was observed during the three 6-mo periods between birth and 18 mo, but a significant correlation between a change in serum GHBP and a change in serum IGF-I or IGFBP-3 levels was only seen between 12 and 18 mo of age (Fig. 5) . Table 3 shows the multiple regression model for length velocity between 6 and 12 mo against the variables observed during the same period (r 2 ϭ 0.43, p ϭ 0.0002). The change in serum GHBP and IGF-I concentrations between 6 and 12 mo of age and the age of onset of childhood phase of growth could explain 43% of the length gain between 6 and 12 mo of age in our babies.
DISCUSSION
The growth velocity during infancy is the highest during the growth process from birth to mature height. In early infancy, GH levels are high whereas circulating IGF-I and IGFBP-3 concentrations are low relative to older children and adults (3, 8 -10) . The high circulating GH levels in infancy may be the result of a lack of negative feedback from the relatively low concentrations of circulating IGF-I and low levels of GH receptors in tissues of infants, suggesting a degree of GH resistance (11) (12) (13) . IGF-I is an important factor of embryonic and fetal differentiation and growth, and there is evidence that insulin rather than GH is the important determinant in fetal IGF-I production (1, 28) . However, in recent animal studies, fetal IGF-I levels have been found to be significantly lower in GH-deficient fetuses than in those with normal GH levels, suggesting a minor role for GH in the regulation of fetal IGF-I and their binding proteins (29) . Growth-retarded newborn infants have been shown to have higher serum GH and lower IGF-I concentrations (9, 30) . In human fetuses throughout the second half of gestation, serum levels of IGF-I and IGFBP-3 concentrations have been found to be significantly inversely correlated to serum levels of GH, implying that fetal IGF-I and IGFBP-3 control could be influenced by pituitary GH secretion in addition to the predominant nutritional influence on these growth factors (30) . During early neonatal life, serum IGF-I levels continue to be nutritionally dependent because an increase in serum IGF-I levels in the first 3 mo of life has been found to be associated with weight gain and hence increased nutrient intake after intrauterine nutrient deprivation (24) . Even in children and adults, circulating IGF-I concentrations are significantly influenced by nutrient and caloric intake, falling with food restriction and rising on refeeding (31). We found a positive correlation between the change in serum IGF-I and length gain and change in BMI in the normal infants in our study during the first 6 mo of life. BMI change is a wellrecognized index of nutritional status. This finding supports the suggestion that nutrition is one of the most important regulators of serum IGF-I concentrations in early infancy. A clear rise in serum insulin and pulsatile GH secretion had been observed after feeding in a group of appropriate-for-gestational-age neonates (3). In our study, we could not find any significant correlation of serum IGF-I and IGFBP-3 levels with caloric or protein intake. It is likely that the infants in our study were all well nourished.
Pulsatile GH secretion has been demonstrated in preterm and term newborn infants (3, 32) . The pulse periodicity of 2.5-3 h is similar to that observed in older children and adults, but the pulse amplitudes are higher (3, 33) . GHBP, which corresponds to the extracellular domain of the GHR, is generated in humans by proteolytic cleavage of the ectodomain of the membranebound GHR (34, 35) . GHR and GHBP concentrations are very low in the fetus and neonate (12, 13, 36, 37) and rise rapidly during infancy and progressively slower in childhood and adolescence to stabilize in the late teens (12, (37) (38) (39) . It has been suggested that circulating GHBP level may serve as a useful index of tissue GHR responsiveness in humans in whom direct receptor measurements are difficult, but recently reservations have been raised about its isolated measurement in the assessment of GHR responsiveness without additional detailed tests of the entire GH-IGF-I axis (35) . After late infancy and early childhood, serum IGF-I and IGFBP-3 concentrations become GH dependent. Serum IGF-I levels have been shown to correlate with endogenous GH secretion in pathologic and physiologic conditions (16) . The serum GHBP levels had been found to correlate inversely with 24-h GH secretion in healthy boys of normal stature, and this reciprocal relationship between these two measurements was suggested as a reflection of the balance between GH production and GH action, which would be required to achieve the genetically programmed height (40) . As frequent sampling for GH overnight or over 24 h is not practical in infants and young children, we decided to measure serum GHBP level in the infants of our study as an indicator of GHR responsiveness, despite the recent reservations (35) , and serum IGF-I and IGFBP-3 as surrogate markers of GH action on growth, although admittedly IGF-I and IGFBP-3 could also be influenced by factors (e.g. age, nutrition, sex hormones) other than GH itself (16) .
The mean age of onset of the childhood phase of growth in our cohort of normal Chinese infants was 9.9 mo for boys and 9.6 mo for girls, which was not significantly different from that derived from a Swedish longitudinal growth cohort (26) . This suggests that growth faltering, which is commonly seen in developing countries (41) , is no longer evident in present-day Chinese infants in Hong Kong, and this is the result of improvement in the socioeconomic status and health care in Hong Kong in the past 20 y (27). In our longitudinal study of serum GHBP, IGF-I, and IGFBP-3 concentrations in Chinese infants, there was a significant rise in serum GHBP by 6 mo of age with further rises at 10, 12, and 18 mo. On the contrary, there was no significant rise in serum IGF-I and IGFBP-3 concentrations until 10 mo of age. We have also shown that the 34 infants with an onset of the childhood phase of growth before 10 mo had a significantly higher mean serum IGF-I level at 10 mo of age and a greater length velocity between 10 and 12 mo of age compared with that observed in the 14 infants with the age of onset of the childhood phase of growth occurring after 10 mo of age. A significant association of the change in serum GHBP and the change in serum IGF-I or IGFBP-3 concentration was only demonstrated between 12 and 18 mo of age and not earlier, suggesting that the dependence of serum IGF-I and IGFBP-3 levels on GH does not take place until after the onset 
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of the childhood phase of growth in late infancy. The multiple regression analysis revealed that length velocity between 6 and 12 mo of age was significantly negatively associated with serum GHBP concentration and the age of onset of the childhood phase and positively associated with the serum IGF-I concentrations. Although these associations are not proof of a causal relationship, the results support our hypothesis that the onset of GH-dependent phase of growth occurs in late infancy and is associated with the onset of significant GH action on growth.
In this study we have established longitudinal reference data for serum GHBP, IGF-I, and IGFBP-3 concentrations in normal Chinese babies in the first 18 mo of life. There is an age-dependent increase in GHBP concentrations in early life with a significant increase evident by 6 mo of age, well before the significant increase in serum IGF-I and IGFBP-3 concentrations first noticeable at 10 mo of age. We have provided more detailed information on the changes of serum GHBP levels in early life than is presently available in the literature (12, 13, 37, 38, 42) . The serum IGF-I concentrations were not normally distributed, and there was a wide interindividual variation in the serum levels at the different times of the study (Fig. 1) . The wide variability in the serum IGF-I concentration has been partially attributed to a genetic influence because it has been demonstrated that the within-pair correlation of serum IGF-I values for monozygotic twin pairs was significantly higher than that observed in dizygotic twin pairs of the same sex (24, 43) . The marked variations in the serum concentrations of IGF-I in the first 18 mo of life will limit its usefulness in the assessment of growth disorder in early life. Contrary to our study, two previous studies reported little variation in the serum IGF-I concentration in the first 1-2 y of life (10, 24) . The reasons behind this difference in the reported developmental serum growth factors profile are not immediately apparent. Several studies have shown serum-free IGF-I measurements to be useful in the assessment of linear growth in childhood (17, 23, 25, 44) . It is possible that serum-free IGF-I rather than total IGF-I level may be more sensitive to changes in GH secretory status and more useful in growth studies in infancy.
Significant correlation between serum IGF-I and IGFBP-3 concentration was demonstrated in infants from birth to 18 mo of age, consistent with findings from previous studies (10, 24, 30) . A significant increase in serum IGFBP-3 concentration with age was noted in our babies, with a significant rise occurring first at 10 mo of age. Serum IGFBP-3 concentrations have also been found to be partially regulated by nutritional intake (22) . A significant positive association between serum IGFBP-3 levels with BMI and sex has also been demonstrated in healthy infants (17) but no such correlation could be documented in our study cohort from birth to 18 mo of age. The lack of association of linear growth with a change in serum IGFBP-3 concentrations in our multiple regression analysis suggests that its measurement may not be as useful as serum IGF-I and GHBP in the assessment of growth in early life. The significant correlation between serum IGF-I and IGFBP-3 levels at different ages and the significant correlation of the change in IGF-I and the change in IGFBP-3 during the three 6-mo periods during the first 18 mo of life suggest that the changes in the concentrations of these two peptides are developmentally similarly regulated. In summary, we have established reference data for serum GHBP, IGF-I, and IGFBP-3 concentrations in Chinese infants in early life. The results of our study support the hypothesis that the onset of the childhood phase of growth is associated with the onset of significant GH action on growth. The transition to GH dependence of serum IGF-I and IGFBP-3 concentrations takes place in late infancy.
